Beta Bionics (NASDAQ:BBNX) CFO Stephen Feider Sells 5,104 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 5,104 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $17.05, for a total value of $87,023.20. Following the sale, the chief financial officer owned 165,931 shares of the company’s stock, valued at $2,829,123.55. This represents a 2.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Feider also recently made the following trade(s):

• On Monday, June 29th, Stephen Feider sold 4,896 shares of Beta Bionics stock. The stock was sold at an average price of $17.03, for a total value of $83,378.88.
• On Tuesday, June 2nd, Stephen Feider sold 6,676 shares of Beta Bionics stock. The stock was sold at an average price of $12.61, for a total value of $84,184.36.

Beta Bionics Stock Performance

Shares of BBNX opened at $15.67 on Wednesday. Beta Bionics, Inc. has a one year low of $8.80 and a one year high of $32.71. The stock has a 50-day moving average price of $12.28 and a 200 day moving average price of $15.31. The company has a market capitalization of $698.26 million, a P/E ratio of -10.38 and a beta of 3.40.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%.The company had revenue of $27.63 million for the quarter. As a group, equities research analysts forecast that Beta Bionics, Inc. will post -2.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on BBNX shares. Bank of America reduced their price target on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research report on Monday, May 18th. Weiss Ratings cut shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Truist Financial reduced their price target on shares of Beta Bionics from $25.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, April 15th. Stifel Nicolaus decreased their price target on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Finally, Leerink Partners lowered their price objective on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.70.

Hedge Funds Weigh In On Beta Bionics

Institutional investors have recently modified their holdings of the company. Perceptive Advisors LLC increased its position in Beta Bionics by 39.8% in the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock valued at $8,446,000 after acquiring an additional 240,000 shares during the period. Eversept Partners LP raised its position in shares of Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after buying an additional 736,576 shares in the last quarter. Quantinno Capital Management LP raised its position in shares of Beta Bionics by 112.9% during the 1st quarter. Quantinno Capital Management LP now owns 67,879 shares of the company’s stock worth $680,000 after buying an additional 35,996 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Beta Bionics in the 1st quarter worth approximately $720,000. Finally, Granahan Investment Management LLC lifted its stake in shares of Beta Bionics by 104.9% in the 1st quarter. Granahan Investment Management LLC now owns 248,449 shares of the company’s stock worth $2,489,000 after acquiring an additional 127,203 shares during the period.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.